Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial

AtaiBeckley

25/07/2025 21:14

July 25 (Reuters) - Atai Life Sciences 9VC.DE and its partner Recognify Life Sciences said on Friday their experimental drug did not meet the main goal in a mid-stage trial for patients with cognitive impairment linked to schizophrenia.

U.S.-listed shares of atai fell about 14% in extended trading.

 (Reporting by Kamal Choudhury in Bengaluru; Editing by Devika Syamnath)

 ((Kamal.Choudhury@thomsonreuters.com;))